IGM Biosciences Inc
NASDAQ:IGMS

Watchlist Manager
IGM Biosciences Inc Logo
IGM Biosciences Inc
NASDAQ:IGMS
Watchlist
Price: 1.27 USD -2.31% Market Closed
Market Cap: 76.6m USD

Net Margin
IGM Biosciences Inc

-36.5%
Current
-15 493%
Average
-6.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-36.5%
=
Net Income
-53m
/
Revenue
145.1m

Net Margin Across Competitors

No Stocks Found

IGM Biosciences Inc
Glance View

Market Cap
76.2m USD
Industry
Biotechnology

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. The company is headquartered in Mountain View, California and currently employs 192 full-time employees. The company went IPO on 2019-09-18. The company has developed an IgM antibody technology platform that is particularly well suited for developing T cell engagers, receptor cross-linking agonists and targeted cytokines. Its lead product candidate, IGM-2323, a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins, is in an ongoing Phase I clinical trial for the treatment of relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL) patients. Its second product candidate, IGM-8444, is an IgM antibody targeting Death Receptor 5 (DR5) proteins, which is for the treatment of patients with solid and hematologic malignancies. The Company’s pipeline also includes IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.

IGMS Intrinsic Value
HIDDEN
Show
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-36.5%
=
Net Income
-53m
/
Revenue
145.1m
What is the Net Margin of IGM Biosciences Inc?

Based on IGM Biosciences Inc's most recent financial statements, the company has Net Margin of -36.5%.

Back to Top